Trial · NCT04991753
Outcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in Disease Activity Index Score 28 Using C-reactive Protein (DAS28-CRP) at Week 12 | Baseline (Week 0), Week 12 | The full analysis set (FAS) included all randomized participants who received at least 1 dose (partial or complete) of any study intervention. | Score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Percentage of Participants Who Achieved American College of Rheumatology (ACR) 20 at Week 12 | Week 12 | The full analysis set (FAS) included all randomized participants who received at least 1 dose (partial or complete) of any study intervention. | Percentage of Participants | NUMBER |
| SECONDARY | Percentage of Participants Who Achieved American College of Rheumatology (ACR) 50 at Week 12 | Week 12 | The full analysis set (FAS) included all randomized participants who received at least 1 dose (partial or complete) of any study intervention. | Percentage of Participants | NUMBER |
| SECONDARY | Percentage of Participants Who Achieved American College of Rheumatology (ACR) 70 at Week 12 | Week 12 | The full analysis set (FAS) included all randomized participants who received at least 1 dose (partial or complete) of any study intervention. | Percentage of Participants | NUMBER |
| SECONDARY | Percentage of Participants Who Achieved American College of Rheumatology (ACR) 90 at Week 12 | Week 12 | The full analysis set (FAS) included all randomized participants who received at least 1 dose (partial or complete) of any study intervention. | Percentage of Participants | NUMBER |
| SECONDARY | Percentage of Participants Who Achieved Disease Activity Index Score 28 Using C-reactive Protein (DAS28-CRP) Remission at Week 12 | Week 12 | The full analysis set (FAS) included all randomized participants who received at least 1 dose (partial or complete) of any study intervention. | Percentage of Participants | NUMBER |
| SECONDARY | Percentage of Participants Who Achieved Disease Activity Index Score 28 Using C-reactive Protein (DAS28-CRP) Low Disease Activity (LDA) European League Against Rheumatism (EULAR) at Week 12 | Week 12 | The full analysis set (FAS) included all randomized participants who received at least 1 dose (partial or complete) of any study intervention. | Percentage of Participants | NUMBER |
| SECONDARY | Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Week 12 | Baseline (Week 0), Week 12 | The full analysis set (FAS) included all randomized participants who received at least 1 dose (partial or complete) of any study intervention. | Score on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | From Week 0 up to 8 weeks post last dose at Week 10 (up to Week 18) | The safety analysis set included all randomized participants who received at least 1 dose (partial or complete) of any study intervention. | Percentage of Participants | NUMBER |
| SECONDARY | Percentage of Participants With Treatment-emergent Serious Adverse Events (TESAEs) | From Week 0 up to 8 weeks post last dose at Week 10 (up to Week 18) | The safety analysis set included all randomized participants who received at least 1 dose (partial or complete) of any study intervention. | Percentage of Participants | NUMBER |
| SECONDARY | Percentage of Participants With AEs Leading to Discontinuation of Study Intervention | From Week 0 up to Week 10 | The safety analysis set included all randomized participants who received at least 1 dose (partial or complete) of any study intervention. | Percentage of Participants | NUMBER |
| SECONDARY | Percentage of Participants With Treatment-emergent Adverse Events of Special Interest (AESIs) | From Week 0 up to 8 weeks post last dose at Week 10 (up to Week 18) | The safety analysis set included all randomized participants who received at least 1 dose (partial or complete) of any study intervention. | Percentage of Participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04991753/outcomes